Horizon Pharma Inc (NASDAQ:HZNP) Institutional Investor Sentiment Trend

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Logo Sentiment for Horizon Pharma Inc (NASDAQ:HZNP)

Horizon Pharma Inc (NASDAQ:HZNP) institutional sentiment decreased to 0.86 in 2018 Q3 . Its down -0.36, from 1.22 in 2018Q2. The ratio dropped, as 86 funds increased or started new positions, while 100 sold and decreased positions in Horizon Pharma Inc. The funds in our partner’s database now hold: 134.96 million shares, up from 130.42 million shares in 2018Q2. Also, the number of funds holding Horizon Pharma Inc in their top 10 positions decreased from 4 to 3 for a decrease of 1. Sold All: 25 Reduced: 75 Increased: 45 New Position: 41.

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company has market cap of $3.59 billion. The companyÂ’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. It currently has negative earnings. The Company’s products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

The stock increased 0.12% or $0.02 during the last trading session, reaching $21.42. About 880,310 shares traded. Horizon Pharma Public Limited Company (NASDAQ:HZNP) has risen 34.43% since January 25, 2018 and is uptrending. It has outperformed by 34.43% the S&P500.

Analysts await Horizon Pharma Public Limited Company (NASDAQ:HZNP) to report earnings on February, 27. They expect $0.54 EPS, up 86.21 % or $0.25 from last year’s $0.29 per share. HZNP’s profit will be $90.53 million for 9.92 P/E if the $0.54 EPS becomes a reality. After $0.65 actual EPS reported by Horizon Pharma Public Limited Company for the previous quarter, Wall Street now forecasts -16.92 % negative EPS growth.

Venbio Select Advisor Llc holds 4.01% of its portfolio in Horizon Pharma Public Limited Company for 4.46 million shares. Jabodon Pt Co owns 121,158 shares or 3.09% of their US portfolio. Moreover, Jw Asset Management Llc has 2.86% invested in the company for 270,775 shares. The Sweden-based Rhenman & Partners Asset Management Ab has invested 1.8% in the stock. 1492 Capital Management Llc, a Wisconsin-based fund reported 139,313 shares.

Since January 1, 0001, it had 0 insider purchases, and 2 insider sales for $9.00 million activity. Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Coverage

Ratings analysis reveals 25% of Horizon Pharma’s analysts are positive. Out of 4 Wall Street analysts rating Horizon Pharma, 1 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $18 while the high is $24. The stock’s average target of $21.50 is 0.37% above today’s ($21.42) share price. HZNP was included in 4 notes of analysts from August 6, 2018. The firm has “Buy” rating by Jefferies given on Thursday, August 9. As per Thursday, November 15, the company rating was downgraded by Mizuho. BMO Capital Markets downgraded Horizon Pharma Public Limited Company (NASDAQ:HZNP) on Monday, August 6 to “Market Perform” rating. The firm has “Equal-Weight” rating given on Friday, August 17 by Morgan Stanley.

More notable recent Horizon Pharma Public Limited Company (NASDAQ:HZNP) news were published by: Seekingalpha.com which released: “Horizon Pharma Remains Undervalued – Seeking Alpha” on March 14, 2016, also Nasdaq.com with their article: “Horizon Pharma (HZNP) Boasts Robust Pipeline Amid Competition – Nasdaq” published on August 22, 2018, Globenewswire.com published: “Horizon Pharma plc Announces the Launch of “Cystinosis United†to Educate, Inspire and Connect the Cystinosis Community – GlobeNewswire” on January 30, 2018. More interesting news about Horizon Pharma Public Limited Company (NASDAQ:HZNP) were released by: Streetinsider.com and their article: “Horizon Pharma (HZNP) Announces FDA Approval to Expand Age Range for RAVICTI Oral Liquid to Include Newborns – StreetInsider.com” published on December 27, 2018 as well as Nasdaq.com ‘s news article titled: “Horizon Pharma’s Ravicti Gets FDA Nod for Expanded Age Group – Nasdaq” with publication date: December 28, 2018. Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Chart

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *